| Seizures, Focal
Qudexy XR vs Vimpat
Side-by-side clinical, coverage, and cost comparison for seizures, focal.Deep comparison between: Qudexy vs Vimpat with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsVimpat has a higher rate of injection site reactions vs Qudexy based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Vimpat but not Qudexy, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Qudexy
Vimpat
At A Glance
Oral
Once daily
Broad-spectrum anticonvulsant
Oral; IV infusion
Twice daily
Sodium channel modulator
Indications
- Seizures, Focal
- Generalized seizures
- Lennox-Gastaut syndrome
- Migraine Disorders
- Seizures, Focal
- Idiopathic generalized epilepsy
Dosing
Seizures, Focal, Generalized seizures, Lennox-Gastaut syndrome Monotherapy (adults and peds >=10 years): 400 mg orally once daily, titrated over 6 weeks from 50 mg/day; peds 2-9 years: weight-based 150-400 mg/day once daily. Adjunctive (adults): 200 to 400 mg once daily; adjunctive (peds 2-16 years): approximately 5 to 9 mg/kg once daily, not to exceed 400 mg/day.
Migraine Disorders 100 mg orally once daily for patients 12 years of age and older, titrated over 4 weeks from 25 mg/day.
Seizures, Focal Monotherapy (adults >=17 years): initiate 100 mg twice daily, maintenance 150-200 mg twice daily (300-400 mg/day); adjunctive therapy (adults): initiate 50 mg twice daily, maintenance 100-200 mg twice daily (200-400 mg/day); pediatric patients 1 month to <17 years: weight-based dosing twice daily; max 200 mg twice daily; IV infusion available at same dose when oral temporarily not feasible.
Idiopathic generalized epilepsy Adjunctive therapy only for patients 4 years of age and older; adults: initiate 50 mg twice daily, titrate by 50 mg twice daily weekly, maintenance 100-200 mg twice daily (200-400 mg/day); pediatric patients: weight-based dosing twice daily.
Contraindications
- History of hypersensitivity reaction to topiramate, QUDEXY XR, or any inactive ingredient
—
Adverse Reactions
Most common (>=10%) Paresthesia, somnolence, dizziness, weight loss, anorexia, speech disorders/related speech problems, psychomotor slowing, nervousness, vision abnormal
Serious Acute myopia and secondary angle closure glaucoma, visual field defects, oligohydrosis and hyperthermia, metabolic acidosis, suicidal behavior and ideation, cognitive/neuropsychiatric adverse reactions, decrease in bone mineral density, negative effects on growth, DRESS/multiorgan hypersensitivity, serious skin reactions, anaphylaxis and angioedema, hyperammonemia and encephalopathy, kidney stones, hypothermia with concomitant valproic acid
Postmarketing Hepatic failure, hepatitis, pancreatitis, bullous skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis), pemphigus, maculopathy, nephrocalcinosis
Most common (>=2%) dizziness, headache, nausea, diplopia, ataxia, somnolence, vomiting, fatigue, blurred vision, vertigo, tremor, nystagmus, balance disorder
Serious suicidal behavior and ideation, dizziness and ataxia, cardiac rhythm and conduction abnormalities, syncope, DRESS/multiorgan hypersensitivity reactions
Postmarketing agranulocytosis, aggression, agitation, hallucination, insomnia, psychotic disorder, angioedema, rash, urticaria, Stevens-Johnson syndrome, toxic epidermal necrolysis, dyskinesia, new or worsening seizures
Pharmacology
Topiramate blocks voltage-dependent sodium channels, augments GABA-A receptor activity, antagonizes the AMPA/kainate subtype of the glutamate receptor, and inhibits carbonic anhydrase isozymes II and IV; the precise mechanisms underlying its anticonvulsant and preventive migraine effects are unknown.
Lacosamide selectively enhances slow inactivation of voltage-gated sodium channels, resulting in stabilization of hyperexcitable neuronal membranes and inhibition of repetitive neuronal firing; it is a functionalized amino acid antiepileptic agent.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Qudexy
- Covered on 5 commercial plans
- PA (7/12) · Step Therapy (0/12) · Qty limit (0/12)
Vimpat
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (1/12) · Qty limit (9/12)
UnitedHealthcare
Qudexy
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Vimpat
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (4/8) · Qty limit (1/8)
Humana
Qudexy
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Vimpat
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Qudexy.
No savings programs available for Vimpat.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
QudexyView full Qudexy profile
VimpatView full Vimpat profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.